Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Contributed by: PR Newswire

Tags

H-Lundbeck-A/S

More Like This

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses